Search

Author/Creator Su, W-C

1. 1392PDose-determination results from a phase Ib/II study of ceritinib (CER) + ribociclib (RIB) in ALK-positive (ALK+) non-small cell lung cancer (NSCLC). (23rd October 2018)

Authors:
Santoro, A; Su, W-C; Navarro, A; Simonelli, M; Yang, J C-H; Ardizzoni, A; Barlesi, F; Kang, J H; Didominick, S; Abdelhady, A; Goswami, B; Crystal, A; Felip, E
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 421PEGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC). (22nd November 2017)

Authors:
Akamatsu, H; Delmonte, A; John, T; Su, W-C; Lee, J-S; Chang, G-C; Huang, X; Jenkins, S; Dearden, S; Wu, Y-L
Journal:
Annals of oncology
Issue:
Volume 28(2017)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 475OOverall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI). (24th November 2019)

Authors:
Wu, Y-L; Mok, T S K; Han, J-Y; Ahn, M-J; Delmonte, A; Ramalingam, S S; Kim, S-W; Shepherd, F A; Laskin, J; He, Y; Akamatsu, H; Theelen, W S M E; Su, W-C; John, T; Sebastian, M; Mann, H; Miranda, M; Laus, G; Rukazenkov, Y; Papadimitrakopoulou, V
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 533TiPCANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx). (24th November 2019)

Authors:
Lim, D; Goto, Y; Cho, B C; Kaneda, H; Kang, J-H; Kim, S-W; Chiu, C-H; Yang, J C-H; Su, W-C; Obyrne, K; Papadimitrakopoulou, V; Reck, M; Malet, I; Mookerjee, B; Zewen, Z; Rodriguez, L Paz-Ares
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 624PDPreliminary results of a ph2a study to evaluate the clinical efficacy and safety of erdafitinib in Asian patients with biomarker-selected advanced cholangiocarcinoma (CCA). (23rd October 2018)

Authors:
Chen, Y-Y; Park, J O; Su, W-C; Oh, D-Y; Kim, K-P; Feng, Y-H; Shen, L; Liao, H; Nie, J; Qing, M; Li, J; De Porre, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. LBA2TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI. (24th November 2019)

Authors:
Han, J-Y; Sequist, L V; Ahn, M-J; Cho, B C; Yu, H; Kim, S-W; Yang, J C-H; Lee, J S; Su, W-C; Kowalski, D; Orlov, S; Cantarini, M; Verheijen, R B; Mellemgaard, A; Frewer, P; Ou, X; Oxnard, G
Journal:
Annals of oncology
Issue:
Volume 30(2019)Supplement 9
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. LBA4Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro. (17th December 2018)

Authors:
Herbst, R S; Garon, E B; Kim, D-W; Chul Cho, B; Pérez Gracia, J L; Han, J-Y; Dubos Arvis, C; Majem, M; Forster, M; Monnet, I; Novello, S; Szalai, Z; Gubens, M A; Su, W-C; Ceresoli, G L; Samkari, A; Jensen, E; Lubiniecki, G M; Baas, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 10
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. LBA63Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). (23rd October 2018)

Authors:
Herbst, R S; Garon, E B; Kim, D-W; Chul Cho, B; Pérez Gracia, J L; Han, J-Y; Dubos Arvis, C; Majem, M; Forster, M; Monnet, I; Novello, S; Szalai, Z; Gubens, M A; Su, W-C; Ceresoli, G L; Samkari, A; Jensen, E; Lubiniecki, G M; Baas, P
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗